Satoshi Nozaki1, Naoko Ozaki2, Shinobu Suzuki2, Miki Goto3, Aya Mawatari3, Yuka Nakatani3, Emi Hayashinaka3, Yasuhiro Wada3, Hisashi Doi3, Yasuyoshi Watanabe3,4. 1. RIKEN Center for Life Science Technologies, 6-7-3 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. satoshi.nozaki@riken.jp. 2. Department of Molecular and Cellular Biology, Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Ltd, Kobe, Hyogo, Japan. 3. RIKEN Center for Life Science Technologies, 6-7-3 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan. 4. Department of Physiology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Abstract
PURPOSE: In vivo detection of pathological insults during the early stages of rheumatoid synovitis is essential to allow early anti-inflammatory treatment for prevention of joint destruction. Whether rheumatoid synovitis pathology and the efficacy of therapies can be visualized by positron emission tomography (PET) tracers specific to the inflammatory process was investigated. PROCEDURES: Using a collagen-induced experimental rat model of rheumatoid arthritis, in vivo imaging using the PET tracers [11C]PK11195, which binds to the translocator protein mainly expressed on myeloid cells, and [11C]ketoprofen, for cyclooxygenase imaging, was performed. To evaluate therapeutic efficacy, model animals were administered the tumour necrosis factor alpha blocker etanercept subcutaneously. RESULTS: [11C]PK11195 and [11C]ketoprofen uptakes were significantly higher in inflamed paws of collagen-induced arthritis rats than in normal rats. The data showed a correlation between tracer uptake values and paw swelling. After treatment with etanercept, [11C]ketoprofen uptake was significantly lower in treated animals than in untreated ones, whereas [11C]PK11195 uptake in the inflamed regions was comparable to that in the untreated group. CONCLUSIONS: With [11C]PK11195 and [11C]ketoprofen tracers, non-invasive in vivo PET imaging for rheumatoid synovitis can provide diagnostic evidence of early synovitis and allow monitoring inflammatory cell activity during treatment.
PURPOSE: In vivo detection of pathological insults during the early stages of rheumatoid synovitis is essential to allow early anti-inflammatory treatment for prevention of joint destruction. Whether rheumatoid synovitis pathology and the efficacy of therapies can be visualized by positron emission tomography (PET) tracers specific to the inflammatory process was investigated. PROCEDURES: Using a collagen-induced experimental rat model of rheumatoid arthritis, in vivo imaging using the PET tracers [11C]PK11195, which binds to the translocator protein mainly expressed on myeloid cells, and [11C]ketoprofen, for cyclooxygenase imaging, was performed. To evaluate therapeutic efficacy, model animals were administered the tumour necrosis factor alpha blocker etanercept subcutaneously. RESULTS: [11C]PK11195 and [11C]ketoprofen uptakes were significantly higher in inflamed paws of collagen-induced arthritisrats than in normal rats. The data showed a correlation between tracer uptake values and paw swelling. After treatment with etanercept, [11C]ketoprofen uptake was significantly lower in treated animals than in untreated ones, whereas [11C]PK11195 uptake in the inflamed regions was comparable to that in the untreated group. CONCLUSIONS: With [11C]PK11195 and [11C]ketoprofen tracers, non-invasive in vivo PET imaging for rheumatoid synovitis can provide diagnostic evidence of early synovitis and allow monitoring inflammatory cell activity during treatment.
Entities:
Keywords:
Cyclooxygenase; Early diagnostic techniques; Positron emission tomography; Rheumatoid arthritis; Translocator protein
Authors: Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo Journal: Arthritis Rheum Date: 2002-04
Authors: Yoony Y J Gent; Alexandre E Voskuyl; Reina W Kloet; Dirkjan van Schaardenburg; Otto S Hoekstra; Ben A C Dijkmans; Adriaan A Lammertsma; Conny J van der Laken Journal: Arthritis Rheum Date: 2012-01
Authors: X Canat; A Guillaumont; M Bouaboula; C Poinot-Chazel; J M Derocq; P Carayon; G LeFur; P Casellas Journal: Biochem Pharmacol Date: 1993-08-03 Impact factor: 5.858
Authors: Ingo M Irmler; Thomas Opfermann; Peter Gebhardt; Mieczyslaw Gajda; Rolf Bräuer; Hans P Saluz; Thomas Kamradt Journal: Arthritis Res Ther Date: 2010-11-03 Impact factor: 5.156
Authors: Fatemeh Khodadust; Aiarpi Ezdoglian; Maarten M Steinz; Judy R van Beijnum; Gerben J C Zwezerijnen; Gerrit Jansen; Sander W Tas; Conny J van der Laken Journal: Int J Mol Sci Date: 2022-06-25 Impact factor: 6.208
Authors: Durga M S H Chandrupatla; Carla F M Molthoff; Adriaan A Lammertsma; Conny J van der Laken; Gerrit Jansen Journal: Drug Deliv Transl Res Date: 2019-02 Impact factor: 4.617